Valneva SE (VALN) Net Equity Issued and Repurchased (2021 - 2023)
Valneva SE (VALN) posted Net Equity Issued and Repurchased of $48986.6 for Q3 2023, up 149.44% sequentially from -$99092.1 in Q2 2023, and up 115.67% YoY from $22713.4 in Q3 2022.
Valneva SE (VALN) Net Equity Issued and Repurchased (2021 - 2023) Analysis & Trends
Valneva SE has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $48986.6 in Q3 2023.
- Quarterly Net Equity Issued and Repurchased rose 115.67% year-over-year to $48986.6 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $97.5 million (down 49.68% YoY) and the FY2022 annual result came in at $200.1 million, up 1.48% from the prior year.
- Net Equity Issued and Repurchased climbed to $48986.6 in Q3 2023 per VALN's latest filing, from -$99092.1 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $99.9 million in Q2 2021 and troughed at -$312565.0 in Q3 2022.
- A 3-year average of $35.8 million and a median of $2.7 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased sank 128.49% in 2022, then surged 115.67% in 2023.
- Over 3 years, Net Equity Issued and Repurchased stood at $93.3 million in 2021, then increased by 4.81% to $97.8 million in 2022, then plunged by 99.95% to $48986.6 in 2023.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $48986.6, -$99092.1, and -$208228.3 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 48,986.57 |
| Sep 30, 2023 | 48,986.57 |
| Jun 30, 2023 | -99,092.12 |
| Jun 30, 2023 | -99,092.12 |
| Mar 31, 2023 | -208,228.31 |
| Mar 31, 2023 | -208,228.31 |
| Dec 31, 2022 | 97.78 Mn |
| Dec 31, 2022 | 97.78 Mn |
| Sep 30, 2022 | -312,565.04 |
| Sep 30, 2022 | -312,565.04 |
| Jun 30, 2022 | 96.66 Mn |
| Jun 30, 2022 | 96.66 Mn |
| Mar 31, 2022 | 4.18 Mn |
| Mar 31, 2022 | 4.18 Mn |
| Dec 31, 2021 | 93.29 Mn |
| Dec 31, 2021 | 93.29 Mn |
| Sep 30, 2021 | -136,797.33 |
| Sep 30, 2021 | -136,797.33 |
| Jun 30, 2021 | 99.92 Mn |
| Jun 30, 2021 | 99.92 Mn |